<DOC>
	<DOCNO>NCT01701375</DOCNO>
	<brief_summary>1.1 Primary Objectives - To determine feasibility , tolerability , toxicity administer selective CDK 4/6 inhibitor PD 0332991 prior combination ara-C Mitoxantrone adult relapse refractory acute leukemia high risk myelodysplasias ( MDS ) , include primary refractory disease - To determine direct cytotoxic effect single agent PD 0332991 malignant blast - To determine maximal tolerate dose ( MTD ) PD 0332991 time sequential combination ara-C Mitoxantrone - To determine time sequential combination PD 0332991 ara-C mitoxantrone induce clinical response adult relapse refractory acute leukemias high-risk MDS 1.2 Secondary Objectives : - To determine ability PD 0332991 directly induce apoptosis malignant cell population vivo - To obtain pharmacodynamic ( PD ) data regard ability PD 0332991 arrest malignant cell G 1 phase cell cycle , follow synchronized release cell S phase upon discontinuation PD 0332991 resultant enhance ara-C cytotoxicity</brief_summary>
	<brief_title>A Phase 1 Trial TST PD 0332991 Followed Cytarabine Mitoxantrone Adults With Relapsed Refractory Acute Leukemias High-Risk Myelodysplasia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>Adults age ≥ 18 year Multilineage bone marrow failure Serum creatinine ≤ 2.0 mg/dl Hepatic enzyme ( AST , ALT ) ≤ 3x upper limit normal ( ULN ) Bilirubin ≤ 2.0 mg/dl , unless due Gilbert 's disease , hemolysis leukemic infiltration Left ventricular ejection fraction ≥ 45 % QTc ≤ 470 msec RB expression require action PD 0332991 . Because rb deletion mutation rare acute leukemia MDS , screen RB expression require enrollment . Pretreatment biopsy store analyzed RB expression need subsequently . • No 5 cytotoxic regimen Previous allogeneic autologous stem cell transplantation permit ≥ 3 week delay prior cytotoxic chemotherapy radiation therapy ≥ 2 week delay prior biologic therapy include hematopoietic growth factor vidaza decitabine If use Hydroxyurea , steroid , tyrosine kinase/src kinase inhibitor , arsenic , interferon count control , must therapy ≥ 48 hour prior begin PD 0332991 No concomitant use potent CYP450 3A4 inhibitor ( e.g . triazole antifungal agent ) inducer ( e.g . omperazole , dilantin , dexamethasone ) within 7 day prior begin PD 0332991</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>